A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E. coli

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Rognoni, Paola ^a   Lavatelli, Francesca ^a   Casarini, Simona ^a   Palladini, Giovanni ^a   Verga, Laura ^b   Pedrazzoli, Paolo ^b   Valentini, Giovanna ^a   Merlini, Giampaolo ^a   Perfetti, Vittorio ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; BENCE JONES PROTEIN; HOMODIMER; IMMUNOGLOBULIN LIGHT CHAIN; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CASE REPORT; CELL INCLUSION; CONTROLLED STUDY; DISULFIDE BOND; DNA SEQUENCE; ESCHERICHIA COLI; EXPRESSION VECTOR; HEART AMYLOIDOSIS; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; KIDNEY DISEASE; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN PURIFICATION; PROTEIN REFOLDING; SOLUBILIZATION;

AMYLOID; AMYLOIDOSIS; BENCE JONES PROTEIN; CHROMATOGRAPHY, GEL; CIRCULAR DICHROISM; CLONING, MOLECULAR; DNA PRIMERS; ESCHERICHIA COLI; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; INCLUSION BODIES; MICROSCOPY, ELECTRON; PROTEIN ENGINEERING; PROTEIN FOLDING; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84884695112     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076022     Document Type: Article

References (37)

1. Padlan EA, (1994) Anatomy of the antibody molecule. Mol Immunol 31: 169-217.
2. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, et al. (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47: 673-680.
3. Solomon A, (1985) Light chains of human immunoglobulins. Methods Enzymol 116: 101-121.
4. Connors LH, Jiang Y, Budnik M, Théberge R, Prokaeva T, et al. (2007) Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains. Biochemistry 46: 14259-14271.
5. Omtvedt LA, Bailey D, Renouf DV, Davies MJ, Paramonov NA, et al. (2000) Glycosylation of immunoglobulin light chains associated with amyloidosis. Amyloid 7: 227-244.
6. Merlini G, Stone MJ, (2006) Dangerous small B-cell clones. Blood 108: 2520-2530.
7. Merlini G, Bellotti V, (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349: 583-596.
8. Perfetti V, Casarini S, Palladini G, Vignarelli MC, Klersy C, et al. (2002) Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood 100: 948-953.
9. Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA, (2001) The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 98: 714-720.
10. Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, et al. (2003) Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 101: 3801-3808.
11. Perfetti V, Palladini G, Casarini S, Navazza V, Rognoni P, et al. (2012) The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood 119: 144-150.
12. Baglioni S, Casamenti F, Bucciantini M, Luheshi LM, Taddei N, et al. (2006) Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci 26: 8160-8167.
13. Uversky VN, (2010) Mysterious oligomerization of the amyloidogenic proteins. FEBS J 277: 2940-2953.
14. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, et al. (2006) Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107: 3854-3858.
15. Liao R, Jain M, Teller P, Connors LH, Ngoy S, et al. (2001) Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104: 1594-1597.
16. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, et al. (2004) Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 94: 1008-1010.
17. Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, et al. (2010) Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 107: 4188-4193.
18. Lavatelli F, Brambilla F, Valentini V, Rognoni P, Casarini S, et al. (2011) A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. Biochim Biophys Acta 1814: 409-419.
19. Skerra A, (1993) Bacterial expression of immunoglobulin fragments. Curr Opin Immunol 5: 256-262.
20. Perfetti V, Sassano M, Ubbiali P, Vignarelli MC, Arbustini E, et al. (1996) Inverse polymerase chain reaction for cloning complete human immunoglobulin variable regions and leaders conserving the original sequence. Anal Biochem 239: 107-109.
21. Lilie H, Schwarz E, Rudolph R, (1998) Advances in refolding of proteins produced in E. coli. Curr Opin Biotechnol 9: 497-501.
22. De Bernardez Clark E, Schwarz E, Rudolph R, (1999) Inhibition of aggregation side reactions during in vitro protein folding. Methods Enzymol 309: 217-236.
23. Andrade MA, Chacón P, Merelo JJ, Morán F, (1993) Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. Protein Eng 6: 383-390.
24. Sreerama N, Venyaminov SY, Woody RW, (1999) Estimation of the number of alpha-helical and beta-strand segments in proteins using circular dichroism spectroscopy. Protein Sci 8: 370-380.
25. Sreerama N, Woody RW, (2000) Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. Anal Biochem 287: 252-260.
26. Ren R, Hong Z, Gong H, Laporte K, Skinner M, et al. (2010) Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils. J Biol Chem 285: 37672-37682.
27. Klunk WE, Pettegrew JW, Abraham DJ, (1989) Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem Cytochem 37: 1273-1281.
28. Colombo R, Carotti A, Catto M, Racchi M, Lanni C, et al. (2009) CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity. Electrophoresis 30: 1418-1429.
29. Honegger A, Plückthun A, (2001) The influence of the buried glutamine or glutamate residue in position 6 on the structure of immunoglobulin variable domains. J Mol Biol 309: 687-699.
30. Hurle MR, Helms LR, Li L, Chan W, Wetzel R, (1994) A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci U S A 91: 5446-5450.
31. Wall J, Schell M, Murphy C, Hrncic R, Stevens FJ, et al. (1999) Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry 38: 14101-14108.
32. Raffen R, Dieckman LJ, Szpunar M, Wunschl C, Pokkuluri PR, et al. (1999) Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains. Protein Sci 8: 509-517.
33. Klimtchuk ES, Gursky O, Patel RS, Laporte KL, Connors LH, et al. (2010) The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain. Biochemistry 49: 9848-9857.
34. Levinson RT, Olatoye OO, Randles EG, Howell KG, DiCostanzo AC, et al. (2013) Role of mutations in the cellular internalization of amyloidogenic light chains into cardiomyocytes. Sci Rep 3: 1278.
35. Buchner J, Rudolph R, (1991) Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli. Biotechnology (N Y) 9: 157-162.
36. Saxena VP, Wetlaufer DB, (1970) Formation of three-dimensional structure in proteins. I. Rapid nonenzymic reactivation of reduced lysozyme. Biochemistry 9: 5015-5023.
37. Mo H, Moore RC, Cohen FE, Westaway D, Prusiner SB, et al. (2001) Two different neurodegenerative diseases caused by proteins with similar structures. Proc Natl Acad Sci U S A 98: 2352-2357.